Pembrolizumab Ups Survival in NSCLC With PD-L1 Expression

This article originally appeared here.
Share this content:
Pembrolizumab Ups Survival in NSCLC With PD-L1 Expression
Pembrolizumab Ups Survival in NSCLC With PD-L1 Expression

TUESDAY, Oct. 11, 2016 (HealthDay News) -- Pembrolizumab is associated with longer progression-free and overall survival for patients with non-small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression on at least 50 percent of tumor cells, according to a study published online Oct. 9 in the New England Journal of Medicine. The research was published to coincide with the annual European Society of Medical Oncology Congress, held from Oct. 7 to 11 in Copenhagen, Denmark.

Martin Reck, M.D., Ph.D., from the Lung Clinic Grosshansdorf in Germany, and colleagues conducted a phase 3 trial involving 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50 percent of tumor cells. Patients were randomized to receive either pembrolizumab or platinum-based chemotherapy.

The researchers found that median progression-free survival was 10.3 and 6.0 months in the pembrolizumab and chemotherapy groups, respectively (hazard ratio for disease progression or death, 0.50). At six months, the estimated rate of overall survival was 80.2 and 72.4 percent, respectively, in the pembrolizumab and chemotherapy groups (hazard ratio for death, 0.60). The pembrolizumab group had higher response rate (44.8 versus 27.8 percent), as well as longer median duration of response and less frequent treatment-related adverse events of any grade.

"In patients with advanced NSCLC and PD-L1 expression on at least 50 percent of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy," the authors write.

The study was funded by Merck, the manufacturer of pembrolizumab.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Dupixent to Treat Eczema

FDA Approves Dupixent to Treat Eczema

Active ingredient binds to protein (interleukin-4 receptor alpha subunit) that causes inflammation

Arm, Hand Function Restored in Tetraplegic Patient

Arm, Hand Function Restored in Tetraplegic Patient

Researchers utilized functional electric stimulation + intracortical brain-computer interface system

Total Knee Replacement Typically Has Minimal Impact on QoL

Total Knee Replacement Typically Has Minimal Impact on ...

Cost-effectiveness of the procedure could increase if restricted to more severely affected patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »